Cypress Bioscience, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cypress Bioscience, Inc.
The performances of the leading medtechs in the first year of the COVID pandemic were impossible to compare and certainly unrepresentative of normal business cycles and competitive activity. Elective care was largely put on hold and emergency needs boosted exceptional demand for certain product types. More than anything else, 2020 tested management's planning skills.
Rune Labs will collect data from 1,000 patients fitted with Medtronic’s Percept DBS device and search for previously unknown patterns in Parkinson’s disease patients.
How can stakeholders capitalize on this moment of acute public awareness of diagnostics to improve adoption of tests and screening in the long term? At a recent roundtable event, the CEOs of Roche Diagnostics, GE Healthcare, Labcorp and Synlab, among others, gave their thoughts on how the system must change.
Private Company Edition: The industry raised $28bn in venture capital through the third quarter, breaking the record $27.4bn raised last year. Also, big pharmas backed a start-up lab in Israel, plus mega-rounds for CinCor Pharma ($143m) and Rectify Pharmaceuticals ($100m), while Cerecin raises $40m.
- Medical Devices
In Vitro Diagnostics
- Therapeutic Drug Monitoring
- Other Names / Subsidiaries
- Cellatope Corporation
- Proprius Pharmaceuticals, Inc., Ramius LLC
- Royalty Pharma